CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Since its breakthrough development more than a decade ago, CRISPR has revolutionized DNA ... the source of mutational edits and related risks emerging from potentially problematic edits.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

Key risks with CRISPR have migrated over time from concern about achieving end points in its trials, to whether the FDA would approve a CRISPR-based treatment, to know how successful that ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

-2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...